The spleen tyrosine kinase Syk has predominantly been studied in hematopoietic cells in which it is involved in immunoreceptor-mediated signaling. Recently, Syk expression was evidenced in numerous nonhematopoietic cells and shown to be involved in tumor formation and progression. The Syk downstream signaling effectors in nonhematopoietic cells remain, however, to be uncovered, and were investigated using MS-based quantitative phosphoproteomics. Two strategies, based on the inhibition of the Syk catalytic activity and on the loss of Syk expression were employed to identify phosphotyrosine-dependent complexes. Quantitative measurements were obtained on 350 proteins purified with phosphotyrosine affinity columns using the SILAC method. Forty-one proteins are dependent on both Syk expression and catalytic activity and were selected as signaling effectors. They are involved in a variety of biological processes such as signal transduction, cell-cell adhesion and cell polarization. We investigated the functional involvement of Syk in cell-cell adhesion and demonstrated the phosphorylation of E-cadherin and acatenin. In addition, Syk is localized at cell-cell contacts, and Syk-mediated phosphorylation of E-cadherin seems to be important for the proper localization of p120-catenin at adherens junctions. Identification of the biochemical pathways regulated by Syk in human cancer cells will help to uncover its role in tumor formation and progression.
Introduction
The nonreceptor spleen tyrosine kinase Syk has for a long time been considered as a hematopoietic cellspecific signaling molecule. In these cells, Syk is involved in coupling activated immunoreceptors (for example, BCR, TCR, Fc-receptors) to downstream signaling events affecting cell proliferation, differentiation and survival (Sada et al., 2001) . Syk is activated on the binding of its tandem SH2 domains to biphosphorylated immunoreceptor tyrosine-based activation motifs present in the intracellular part of immunoreceptors, leading to its autophosphorylation and phosphorylation of its effectors.
Recent observations demonstrated that Syk is also present in nonhematopoietic cells. Its expression was first substantiated in mammary epithelial cells and lowtumorigenic breast cancer cell lines, whereas invasive and metastatic breast cancer cells lacked Syk expression (Coopman et al., 2000) . An increasing number of clinical studies correlate a reduced Syk expression in breast tumors with an increased risk for metastasis formation (Toyama et al., 2003; Moroni et al., 2004) . The observation that Syk transfection in Syk-negative cells reduced tumor growth and metastasis formation in mouse xenotransplantation models for breast cancer (Coopman et al., 2000) and melanoma (Hoeller et al., 2005) attributes an antioncogenic activity to Syk. Reminiscent of many established tumor suppressor genes, loss of Syk expression is associated with hypermethylation of its promoter in breast cancer (Yuan et al., 2001 ) and other cancer types (Coopman and Mueller, 2006) . The confirmation of Syk expression in numerous nonhematopoietic cell types Coopman and Mueller, 2006) supports its role as an ubiquitous signaling molecule, but its downstream signaling effectors and associated pathways in these cells remain, however, to be uncovered.
In hematopoietic cells, Syk activates a variety of signaling cascades (for example, ras/MAPK, PLCg, PI3K, small GTPases) via the phosphorylation of particular adapter proteins, depending on the cell type, its differentiation status and the nature of immunoreceptor. Alternatively, Syk can also affect the cell behavior more directly by phosphorylating proteins that affect the cytoskeleton such as a-tubulin and cortactin (Maruyama et al., 1996; Peters et al., 1996) . As the molecular mechanisms by which Syk affects breast cancer cell behavior and tumorigenesis currently remain unknown, the identification of its downstream signaling effectors in these cells is of foremost importance. In this context, many adapter proteins phosphorylated by Syk in hematopoietic cells (for example, BLNK, SLP76, LAT) are not expressed by nonhematopoietic cancer cells.
In this study, we attempt to identify novel Syk signaling effectors in human cancer cells by MS-based quantitative proteomics. Using the SILAC (stable isotope labeling with amino acids in cell culture) approach, we performed three extensive large-scale analyses based on a modified Syk catalytic activity or a differential Syk expression. Our study reveals many potential novel Syk effectors and associated signaling pathways and particularly points toward a currently unknown role for Syk in cell-cell adhesion. Figure 1a ). Equal protein-containing lysates of the two cell populations were then mixed and purified on an antiphosphotyrosine affinity column. Enriched phosphotyrosine-dependent complexes (further called signaling effectors) containing phosphorylated and associated proteins were separated by monodimensional SDS-polyacrylamide gel electrophoresis (PAGE), digested with trypsin and subjected to LC-MS/MS. The peptide sequences of isolated proteins were obtained from the MS/MS spectra, allowing their identification with only one specific peptide. Quantification was achieved by determining the relative intensities of the light and heavy Lys-or Arg-labeled tryptic peptides and SILAC ratios were obtained by calculating the ratio between the heavy to light signal intensity. To identify novel Syk signaling effectors in human cancer cells, two major strategies were used. First of all, we compared tyrosine phosphorylation between the Syk-positive MCF7 cells pretreated or not pretreated with the pharmacological Syk inhibitor, piceatannol (Pic; 3, 4, 3 0 ,5 0 -tetrahydroxy-trans-stilbene; Oliver et al., 1994) allowing identification of signaling proteins depending on the Syk catalytic activity. Secondly, we compared tyrosine phosphorylation between MCF7 cells and two Syk-deficient breast cancer cell lines: (1) the MCF7/ADR cell line resistant to adriamycin/doxorubicin and (2) the metastatic MDA-MB-231 cell line. This approach allows identification of potential effectors depending on the Syk expression and the aggressiveness of the tumor cells. As the biological signals and receptors that activate Syk in human cancer cells have not yet been identified, cells were treated with sodium pervanadate (PV), a potent protein tyrosine phosphatase inhibitor and an established activator of the Syk kinase activity (Nagai et al., 1995) . Identification of potential Syk kinase signaling effector proteins in MCF7 cells by inhibiting its catalytic activity (Pic series) To make a first selection of the potential signaling effectors depending on the Syk catalytic activity, optimal Pic treatment conditions on PV-induced global protein tyrosine phosphorylation levels in MCF7 and MDA-MB-231 cells were evaluated by western blotting and quantified by densitometry (Figure 1b ; Supplementary Figure S1a ). The 200 mM Pic concentration was selected as optimal as it decreased the global protein tyrosine phosphorylation in a Syk-dependent manner; 40% inhibition in the Syk-positive MCF7 versus 10% inhibition in the Syk-negative MDA-MB-231 cells. This concentration induced a B50% inhibition of the PVinduced tyrosine phosphorylation of Syk in MCF7 cells which is mainly due to a decreased Syk autophosphorylation (Figure 1b; Supplementary Figure S1b) . It corresponds to the concentration initially reported for inhibition of Syk activity in mast cells (Oliver et al., 1994) . The minor perceptible differences in global PVinduced tyrosine phosphorylation between MCF7 ± Pic and the Syk-negative cell lines (MCF7/ADR and MDA-MB-231; Figure 1c ), illustrate and justify the need of a sensitive and quantitative method for evaluating differential tyrosine phosphorylation such as the SILAC approach.
Results

Strategies
As the selected Pic concentration only partly (B50%) inhibits the Syk catalytic activity in PV-treated cells, proteins with a SILAC ratio greater than 1.1 with full Syk activity are considered as potential Syk signaling effectors. We identified and quantified 350 proteins of which 178 exhibited an increased phosphorylation or association with phosphoproteins in presence of full Syk activity. Interestingly, we retrieved many known Syk substrates that were previously identified in hematopoietic cells and that are also expressed in breast cancer cells, such as DUST3, Cbl, a-tubulin and SHC1, thereby validating our approach. The phosphorylation of several cytoplasmic (Src, FAK1, CSK) and receptor protein tyrosine kinases (EphB4, DDR1) was not affected by the Pic treatment. The observation that the phosphorylation of 56 tyrosine kinases is positively associated with their kinase activity and, therefore, a good readout of their catalytic activity (Rikova et al., 2007) , corroborates the specificity of the Pic concentrations used in our experimental conditions for the Syk kinase activity. The complete list of identified and quantified proteins is detailed in the Supplementary Table S1 .
Selection of Syk kinase signaling effectors based on differential Syk expression
We previously reported that the metastatic MDA-MB-231 breast cancer cells are Syk-negative (Coopman et al., 2000) . Interestingly, the MCF7/ADR cell line resistant to the chemotherapeutic drug doxorubicin lost Syk expression. To identify Syk signaling effectors, two comprehensive SILAC analyses on PV-stimulated cells were performed in parallel: MCF7 versus MCF7/ADR and MCF7 versus MDA-MB-231. As, unlike the Pic Syk þ /P-Tyr SykÀ ) as compared to those from the MCF7/ADR series for all the 177 quantified proteins that were identified in both series. The proteins of the MCF7/ADR series were sorted by descending order of SILAC ratio (black line) and the corresponding proteins from the MDA-MB-231 series (white line) were displayed (logarithmic scale on ordinate). (b) Distribution of the MCF7/ADR series SILAC ratios (P-Tyr Syk þ /P-Tyr SykÀ ) (black line) as compared to those from the MDA-MB-231 series (white line) for the 177 quantified proteins common to both series, as described for (a). (c) Graphic correlation of both series with a logarithmic scale on both axes. The MCF7/ ADR series SILAC ratios are on the x axis and the MDA-MB-231 series ratios on the y axis. The correlation coefficient is indicated in the upper left corner. series, the Syk expression-dependent phosphorylations are clear-cut, a more stringent threshold was applied (ratio >1.3). In the MCF7/ADR series, 203 proteins were quantified and 38 of them were more abundant in the presence of Syk. In the MDA-MB-231 series, 341 proteins were quantified and 59 of them were more abundant in the presence of Syk. The complete list of identified and quantified proteins in these two series is detailed in the Supplementary Table S1 . We next made a global graphic SILAC ratio comparison of the 177 proteins commonly identified in the MCF7/ADR and MDA-MB-231 series. Interestingly, we observed a comparable tyrosine phosphorylation distribution pattern (Figures 2a and b ) and a 0.85 correlation coefficient ( Figure 2c ). Apart from their different genetic background, but concomitant with their Syk-negative status, the MCF7/ADR and MDA-MB-231 cell lines present a correct overall correlation, underlining a reliable Syk effector selection.
The final selection of Syk effectors was based on their dependence on both Syk activity and expression. Only proteins initially retained in the Pic series and also retrieved in at least the MCF7/ADR or the MDA-MB-231 series were taken into account. Forty-one proteins (Figure 3a) . Densitometry quantification of three representative western blots display the same variations as obtained with SILAC quantification (Figure 3b ). (Figures 4b and c) .
DsRed-Syk localizes at MCF7 cell-cell junctions and induces E-cadherin tyrosine phosphorylation in cellulo
To investigate the functional relationship between Syk and E-cadherin in MCF7 cells, we transiently expressed wild-type or kinase-negative (K402R) DsRed-Syk protein. Their subcellular localization and activity using the biphosphorylated activation loop labeling (pTyr-525-526) were studied by confocal microscopy. Wild-type DsRed-Syk colocalizes with E-cadherin and is active at the cell-cell junctions ( Figure 5a ). As this pTyr-525-526 labeling is much less intense than that after PV stimulation (Figure 4a ), we enhanced the Cy5 global fluorescence signal, visualizing the pTyr-525-526 MCF7 nuclear staining (also present in non-PV-stimulated MCF7 cells). Only the DsRed-Syk transfected cell, but not the untransfected neighboring cells, displays activated Syk at the cell-cell junctions. Kinase-negative DsRed-Syk (K402R) also localizes at MCF7 cell-cell junctions but does not exhibit pTyr-525-526 staining (Figure 5a ). Observations in hematopoietic cells demonstrate, nevertheless, that a kinase-dead EGFP Syk fusion protein may exhibit a different spatiotemporal regulation at the plasma membrane as compared to wild-type Syk (Ma et al., 2001; Schymeinsky et al., 2006) . We finally analysed the phosphorylation status of E-cadherin in MCF7 cells transiently expressing wild-type or kinase-negative (K402R) DsRed-Syk ( Figure 5b ). Using western blot, immunoprecipitated E-cadherin shows an enhanced tyrosine phosphorylation only in MCF7 cells transfected with wild-type DsRed-Syk. We verified expression and activity of transfected DsRed-Syk by Syk immunoprecipitation followed by anti-Syk and P-Tyr western blotting, respectively. Only wild-type DsRed-Syk displays a tyrosine-phosphorylated signal in cellulo. Taking together, these results demonstrate that E-cadherin is tyrosine phosphorylated in DsRed-Syk transfected MCF7 cells.
Syk expression and activity are required for the E-cadherin phosphorylation and its interaction with p120-catenin To investigate the biological consequences of E-cadherin phosphorylation by Syk, we inhibited Syk expression using an shRNA approach or Syk activity using pharmacological Syk inhibitors in PV-treated MCF7 cells. A decreased Syk expression resulted in a reduced E-cadherin phosphorylation and concomitantly inhibited the E-cadherin and p120-catenin interaction as evidenced by coimmunoprecipitation experiments (Figure 6a ). These observations were corroborated when inhibiting the Syk catalytic activity with BAY 61-3606 or Pic (Figure 6b ). We next verified whether this decreased interaction resulted in a reduced colocalization of p120-catenin with E-cadherin at cell-cell contacts. Colocalization was displayed in white ( Figure 7a ) and calculated ( Figure 7b ) using ImageJ software. Interestingly, p120-catenin is less present at cell-cell contacts as compared to E-cadherin when Syk expression or activity is inhibited. In conclusion, E-cadherin phosphorylation by Syk seems to be important for the proper localization of p120-catenin at adherens junctions.
Discussion
The Syk tyrosine kinase and its downstream signaling effectors have predominantly been studied in hematopoietic cells. The observation that Syk is also expressed in breast cancer cells and that it negatively affects breast cancer growth and metastasis prompted us to search for its signaling effectors in human cancer cells. Three comprehensive quantitative phosphoproteomic analyses, based on Syk activity and expression, allowed to identify and quantify 350 proteins. Given the large number of proteins that exhibited an increased Syk catalytic activity-dependent abundance, only 41 proteins, appearing in at least two series (catalytic activity and expression), were considered as potential Syk effectors (see Table 1 ). Proteins involved in signal transduction, cell-cell adhesion and cell polarization particularly caught our attention.
The identified signal transduction molecules include the GRB2 and IRS-1 adapter proteins, the PDK1 kinase, the p65 nuclear factor (NF)-kB transcription factor and the SHP-1 protein tyrosine phosphatase. Both GRB2 (von Willebrand et al., 1998) and p65 NF-kB (Bijli et al., 2008) have already been reported to be regulated by tyrosine phosphorylation in a Sykdependent manner. SHP-1 is regulated by tyrosine phosphorylation and was shown to mediate the dephosphorylation of Syk, decreasing its kinase activity (Maeda et al., 1999) . IRS-1 contains multiple tyrosine phosphorylation motifs that serve as docking sites for SH2-domain-containing proteins (for example, GRB2) and its serine phosphorylation was shown to depend on the Syk activity (Xu et al., 2007) . Tyrosine-phosphorylated PDK1 translocates to the plasma membrane in response to insulin (Park et al., 2001) and is recruited concurrently with Syk to lipid rafts (Lang et al., 2002) . The consequences of the tyrosine phosphorylation of these signaling proteins by Syk in human cancer cells remain, however, to be unraveled.
Most intriguingly, the SILAC analysis revealed multiple proteins involved in cell-cell adhesion and cell polarization that have never been reported as Syk effectors. Interestingly, the proportion of these proteins was strikingly enriched in the selected Syk effector list (Table 1 ) as compared to the global list of quantified proteins: cell-cell adhesion proteins 5/41 (12%) versus 13/350 (4%) and cell polarization proteins 5/41 (12%) versus 7/350 (2%). Amongst them, we identified occludin, claudin-3 and ZO-3, all associated with tight junctions, the most apical structures of the epithelial junctional complex that play a role in cell polarity and paracellular transport. Loss of normal tight junction functions constitutes a hallmark of human carcinomas (Gonzalez-Mariscal et al., 2007) . Phosphorylation events play a major role in the regulation of tight junction proteins such as occludin (Feldman et al., 2005) . Other Syk effectors include MAGUK-5, Lin-7C and LAP4/Scribble that form complexes at the basolateral side of epithelial cells. They are crucial for the epithelial architecture, act as molecular scaffolds for signaling pathway components and are gatekeepers to malignancy (Dimitratos et al., 1999) . Syk effectors also include E-cadherin and a-catenin, both major , wild-type (wt) or K402R mutated DsRed-Syk forms were transiently expressed in MCF7 cells. After 48 h, endogenous E-cadherin or Syk were immunoprecipitated and subjected to SDS-polyacrylamide gel electrophoresis (PAGE). The tyrosine phosphorylation status of E-cadherin and the amount of immunoprecipitated E-cadherin were analysed by western blot with respectively anti-P-Tyr and anti-E-cadherin antibodies. Same procedure was applied to analyse Syk expression and activity with respectively anti-Syk and anti-P-Tyr antibodies.
components of the adherens junction complex that is disrupted during breast cancer progression (Berx and Van Roy, 2001 ). We demonstrated their direct phosphorylation by Syk in vitro as well as the induction of E-cadherin tyrosine phosphorylation by transfected DsRed-Syk in cellulo. This direct functional relationship between Syk and two major players in cell-cell adhesion indicates the involvement of Syk in cell-cell adhesion. Syk and E-cadherin promoters are frequently hypermethylated and their expression is downregulated in malignant breast cancer, correlating with poor prognosis (Berx and Van Roy, 2001; Coopman and Mueller, 2006) . Tyrosine phosphorylation of cadherin complexes has been observed and is believed to modulate cell adhesiveness. It has been reported that E-cadherin phosphorylation can disrupt cell-cell contacts (Fujita et al., 2002) . Interestingly, our experiments demonstrate that Syk-mediated phosphorylation of E-cadherin enhances its interaction with p120-catenin and increases their colocalization at adherens junctions. It has been established that the interaction between E-cadherin and p120-catenin is required for the formation of strong adherens junctions (Thoreson et al., 2000) and essential for E-cadherin-mediated suppression of invasiveness (Yanagisawa and Anastasiadis, 2006) . In conclusion, we demonstrate that Syk positively affects the function of adherens junctions. Zolodz et al. (2004) carried out a phosphoproteomic analysis on a Syk-negative chicken B cell line in which Syk expression was restored by transfection with murine Syk and activated with PV. Not using the quantitative SILAC approach, a significantly lesser amount of potential Syk signaling effector proteins were identified, excluding proteins expressed uniquely in nonhematopoietic cells such as the cell-cell adhesion and cell polarization components described above.
The observation that potential Syk effectors belong to such a wide variety of protein families, ranging from signaling molecules to cell-cell adhesion and cell polarization proteins, is consistent with the observation that Syk is involved in processes as diverse as cell division, proliferation, migration, differentiation, factor secretion and gene expression (Coopman and Mueller, 2006) . It is also compatible with the observation that Syk localizes not only to the cytoplasm and the juxtamembrane region, but also to the nucleus (Wang et al., 2005) and the centrosomes . Here, we demonstrate for the first time that Syk is also present and activated at the cell-cell contacts. Consequently, depending on its subcellular localization and the encountered substrates, Syk might specifically affect particular cell activities.
In conclusion, in this pioneering study we used a high-throughput quantitative phosphoproteomic approach to search for Syk kinase effectors in human cancer cells. Our approach allowed to pinpoint 41 proteins, of which most were not previously identified as Syk signaling effectors. It will be a major challenge to elucidate the molecular and biological consequences of Syk activity on these selected proteins. Identification of the biochemical pathways regulated by Syk in nonhematopoietic cells will help to uncover its role in carcinoma formation and progression and may help to conceive novel therapeutic strategies.
Materials and methods
Cell culture and SILAC MCF7 and MDA-MB-231 human breast cancer cell lines were obtained from the American Type Culture Collection Figure 6 Decreased Syk expression or activity reduces E-cadherin phosphorylation and its interaction with p120-catenin. (a) MCF7 cells were stably transfected with control or Syk-targeting shRNA and treated with pervanadate ( þ PV). E-cadherin or p120-catenin were immunoprecipitated and subjected to SDS-polyacrylamide gel electrophoresis (PAGE). The tyrosine phosphorylation status of E-cadherin and the coimmunoprecipitation of p120-catenin were analysed by western blot with anti-P-Tyr, anti-E-cadherin and antip120-catenin antibodies. Same procedure was applied to analyse E-cadherin coimmunoprecipitation with p120-catenin. The consequences of the Syk shRNA transfection on Syk expression (B60% decrease) and the E-cadherin expression (unchanged) were evaluated on total cell lysates. (b) MCF7 cells, preincubated with two different Syk inhibitors BAY 61-3606 (BAY) and piceatannol (Pic) or vehicle (DMSO), were subsequently treated with PV. E-cadherin tyrosine phosphorylation status and p120-catenin coimmunoprecipitation were analysed as in (a).
(Manassas, VA, USA). The doxorubicin-resistant MCF7/ ADR cell line, also called NCI/ADR-RES, was obtained from the Lombardi Cancer Center Tissue Culture Facility (Georgetown University, Washington, DC, USA). All cell lines were maintained as described . MCF7 cells were grown in heavy SILAC medium, whereas the MCF7 cells treated with Pic (1 h, 200 mM (Calbiochem, Darmstadt, Germany)), the MCF7/ADR and MDA-MB-231 cells were grown in light SILAC medium for 7 days (see Supplementary Materials and methods). Alternatively, MCF7 cells were treated with the BAY 61-3606 Syk inhibitor (1 h, 1 or 200 mM (Sigma, St Quentin, Fallavier, France)). Cells were treated with PV (1 mM NaVO 4 þ 1 mM H 2 O 2 ; Sigma) in complete culture medium for 15 min at 37 1C.
Phosphotyrosine immunoaffinity purification and MS analysis Subconfluent cells were lysed in immunoprecipitation buffer . Heavy and light cleared lysates, 5 mg each, were mixed at a 1:1 ratio and incubated overnight at 4 1C with 1 ml of antiphosphotyrosine immunoaffinity beads (see Supplementary Materials and methods). Elution was performed with 100 mM phenyl phosphate (Sigma) and proteins were precipitated with cold acetone. The proteins were separated by 4-15% gradient SDS-PAGE and the gel was stained with the Colloidal Brilliant Blue G (Sigma). Each lane was cut in 45 pieces and protein bands were in-gel digested using trypsin (sequencing grade; Promega, Charbonnie`res, France; Shevchenko et al., 1996) .
Three different series of SILAC analyses were carried out based on differential Syk expression and inhibition of Syk catalytic activity. MS analysis of the samples was performed on a QSTAR pulsar-i quadripole-time-of-flight mass spectrometer (Applied Biosystems, Foster City, CA, USA) coupled to an Ultimate 3000 (Dionex, Amsterdam, Netherland) nanoflow system driven by Chromeleon software (SI Methods). MS/MS spectra were searched against the human entries of UniProt Knowledgebase Release 10.2 database (http:// www.expasy.ch) using the Mascot v2.1 algorithm (http:// www.matrixscience.com). Search parameters were mass accuracy 0.1 Da for MS and MS/MS data; 1 miscleavage; variable modifications: oxidized methionine, Phospho (ST), Phospho (Y), SILAC-labels: Lys-8 and Arg-10. Identification was done on the basis of at least one specific peptide. All significant hits (Po0.05) were manually inspected. Quantification was done on at least two MS spectra per protein using MSQuant v1.4.1 software (Andersen et al., 2003;  http://msquant.sourceforge. net). All MS spectra used for quantification were manually verified. For details, see Supplementary Materials and methods.
Immunoprecipitation and western blotting
Immunoprecipitation and western blot analysis were performed as described . For the source of antibodies, see Supplementary Materials and methods. Densitometry of the western blot chemiluminescence signal was performed using the Image J software (http://rsb. info.nih.gov/ij/).
